Diabetic Ulcer Treatment Market Size to Reach $13.35 Billion by 2027, Driven by the Increasing Number of Company Mergers are a Growing Trend Among Healthcare and Tech Companies

The global diabetic ulcer treatment market size is projected to reach USD 13.53 billion by the end of 2027. The severity associated with foot and mouth ulcers has created a huge emphasis on the development of efficient treatment options. According to a report published by Fortune Business Insights, titled “Diabetic Ulcer Treatment Market Size, Share and Covid-19 Impact Analysis, By Ulcer Type (Foot Ulcer (Neuropathic Ulcer, Ischemic Ulcer, and Neuro-ischemic Ulcer), Mouth Ulcer, and Others), By Treatment Type (Wound-care Dressings, Wound-care Devices, Active Therapies, and Others), By End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Homecare Settings), and Regional Forecast, 2020-2027,” the market was worth USD 8.32 billion in 2019 and will exhibit a CAGR of 6.4% during the forecast period, 2020-2027.

Diabetic ulcers are a common symptom among diabetic patients and almost all patients suffering from diabetes are at the risk of developing ulcers. The severity of ulcers has led to a huge emphasis on the early detection and treatment of the disease. The high investment in the research and development of efficient treatment options will have a direct impact on the growth of the market in the coming years. The increasing prevalence of diabetes across the world will create several growth opportunities for the companies operating in the market. The presence of several healthcare companies involved in R&D of diabetic ulcer treatment options will have a direct impact on the growth of the market in the coming years. Increasing incidence of mouth ulcers and foot ulcers, coupled with the severe symptoms associated with the disease, will bode well for the growth of the market in the foreseeable future.

Orpyx Medical Technologies Introduces New Patient Monitoring System

The report highlights a few of the major industry developments of recent times that have made headlines across the world. Accounting to the severity of ulcers and their rising prevalence across the world, companies are looking to adopt newer strategies that will help them establish a stronghold in the market. In December 2019, Orpyx Medical Technologies announced the launch of a new patient monitoring system. The company introduced ‘Orpyx Sensory Insoles (SI), a product that is used for remote patient monitoring of people suffering from diabetes. The company claims that the product will help detect ulcers at an early stage and help prevent foot as well as neuropathy-related ulcers. The company has a commendable customer base across the world and this product will help the company widen its business. Orpyx’s latest patient monitoring platform will help the company take huge strides, which in turn will emerge in favor of market growth.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/diabetic-ulcer-treatment-market-102412

Lockdowns in Covid-19 Pandemic have Affected Supply Chain of Major Vendors

The recent coronavirus outbreak has had a direct impact on several businesses in the healthcare sector. Although the healthcare companies are least affected, there are numerous businesses that have felt the impact, especially companies that are involved in manufacturing of devices. The Covid-19 pandemic has disrupted supply chains due to the shortage in raw materials as well as lack of workforce.

Major Companies are Focused on Company Mergers

The increasing prevalence of diabetes has created a huge emphasis on treatment options associated with the disease. As a result, healthcare companies are looking to merge with tech companies, with the aim of developing efficient treatment options. It is observed that health-IT mergers are an increasing trend in the global market.

List of companies profiled in the report:

• Coloplast Corp (Denmark)


• Smith & Nephew (UK)


• ConvaTec Group Plc (UK)


• Mölnlycke Health Care AB.(Sweden)


• 3M (U.S.)


• Integra LifeSciences Corporation. (U.S.)


• Cardinal Health. (U.S.)


• Tissue Regenix (U.K)


•  B. Braun Melsungen AG (Germany)

Industry Developments:

• December 2017: SANUWAVE Health, Inc. announced that it has received approval from the US FDA for marketing of the Dermapace System, the first shock wave device intended to treat diabetic foot ulcers.

The global diabetic ulcer treatment market is segmented on the basis of: